Atreca Presents Data from Ongoing Phase 1b Study Of ATRC-101 In Patients With Select Advanced Solid Tumors At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
Atreca presents data from its ongoing Phase 1b study of ATRC-101 in patients with select advanced solid tumors at the 2023 ASCO Meeting. Clinical activity was observed in multiple tumor types, with longer progression-free survival in patients with high target expression. ATRC-101 continues to be well-tolerated, and Phase 2 go/no-go decisions are expected by the end of the year.
June 05, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atreca's ongoing Phase 1b study of ATRC-101 shows positive results in patients with advanced solid tumors. Phase 2 go/no-go decisions are expected by the end of the year.
The positive results from the ongoing Phase 1b study of ATRC-101 indicate potential for the drug's success in treating advanced solid tumors. This could lead to increased investor interest and a positive impact on Atreca's stock price in the short term. The upcoming Phase 2 go/no-go decisions will also be a significant factor in determining the future potential of ATRC-101 and its impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100